+181.4%
XLE vs MRNA
+561.6%
-380.2%
-63.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.9% | -2.2% | +1.4% | -0.9% |
| 7D | +2.2% | +5.5% | -3.3% | +2.2% |
| 30D | +11.8% | +158.7% | -147.0% | +10.3% |
| 3M | +9.8% | +182.1% | -172.3% | +8.0% |
| 6M | +15.6% | +151.8% | -136.2% | +13.9% |
| YTD | +45.3% | +393.6% | -348.3% | +41.0% |
| 1Y | +48.3% | +499.5% | -451.2% | +43.2% |
| 3Y | +55.4% | +29.3% | +26.1% | +52.4% |
| 5Y | +216.1% | -65.1% | +281.2% | +210.6% |
| All | +181.4% | +561.6% | -380.2% | +156.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling